HC Wainwright Expects Stronger Earnings for Biomea Fusion

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Biomea Fusion to a loss of $0.65 per share from $0.69 previously, compared with the consensus estimate of a $0.75 loss. The firm also projects losses of $0.66 in FY2027 and $0.79 in FY2028.
• Biomea Fusion reported a quarterly loss of $0.12 per share, beating analyst expectations for a $0.22 loss by $0.10.
• Analyst sentiment remains generally favorable, with five Buy ratings and one Sell rating, producing a consensus “Moderate Buy” rating and an average price target of $8.20. The stock opened at $1.26, while institutional investors own 96.72% of its shares.

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright lifted their FY2026 earnings per share estimates for shares of Biomea Fusion in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.65) per share for the year, up from their prior estimate of ($0.69). The consensus estimate for Biomea Fusion's current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Biomea Fusion's FY2027 earnings at ($0.66) EPS and FY2028 earnings at ($0.79) EPS.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Biomea Fusion from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, July 1st. Citizens Jmp initiated coverage on shares of Biomea Fusion in a research note on Tuesday, May 5th. They issued a "market outperform" rating and a $9.00 price objective on the stock. Citigroup initiated coverage on shares of Biomea Fusion in a report on Tuesday, May 5th. They issued an "outperform" rating on the stock. D. Boral Capital reissued a "buy" rating and set a $12.00 target price on shares of Biomea Fusion in a research note on Tuesday, April 28th. Finally, Wall Street Zen cut shares of Biomea Fusion from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Biomea Fusion presently has a consensus rating of "Moderate Buy" and an average price target of $8.20.

Biomea Fusion Price Performance

NASDAQ:BMEA opened at $1.26 on Monday. The business's 50-day moving average price is $1.27 and its 200 day moving average price is $1.38. Biomea Fusion has a 52-week low of $0.87 and a 52-week high of $2.99. The firm has a market cap of $91.10 million, a P/E ratio of -4.34 and a beta of -0.28.

Institutional Investors Weigh In On Biomea Fusion

Several hedge funds have recently modified their holdings of the stock. Scientech Research LLC acquired a new stake in shares of Biomea Fusion during the third quarter valued at approximately $25,000. Engineers Gate Manager LP acquired a new position in Biomea Fusion in the 2nd quarter worth approximately $26,000. Millennium Management LLC grew its position in Biomea Fusion by 156.7% during the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company's stock worth $32,000 after purchasing an additional 15,675 shares in the last quarter. Virtu Financial LLC purchased a new position in Biomea Fusion during the 3rd quarter worth approximately $39,000. Finally, State Street Corp raised its stake in Biomea Fusion by 17.8% during the 4th quarter. State Street Corp now owns 165,115 shares of the company's stock valued at $205,000 after purchasing an additional 25,000 shares during the period. 96.72% of the stock is owned by hedge funds and other institutional investors.

About Biomea Fusion

Biomea Fusion, Inc NASDAQ: BMEA is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company's lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source